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Abstract
Objective To evaluate the performance of the QRISK2-2011 score for
predicting the 10 year risk of cardiovascular disease in an independent
UK cohort of patients from general practice and to compare it with earlier
versions of the model and a National Institute for Health and Clinical
Excellence version of the Framingham equation.
Design Prospective cohort study to validate a cardiovascular risk score
with routinely collected data between June 1994 and June 2008.
Setting 364 practices from the United Kingdom contributing to The
Health Improvement Network (THIN) database.
Participants Two million patients aged 30 to 84 years (11.8 million
person years) with 93 564 cardiovascular events.
Main outcome measure First diagnosis of cardiovascular disease
(myocardial infarction, angina, coronary heart disease, stroke, and
transient ischaemic attack) recorded in general practice records.
Results Results from this independent and external validation of
QRISK2-2011 indicate good performance data when compared with the
NICE version of the Framingham equation. QRISK2-2011 had better
ability to identify those at high risk of developing cardiovascular disease
than did the NICE Framingham equation. QRISK2-2011 is well calibrated,
with reasonable agreement between observed and predicted outcomes,
whereas the NICE Framingham equation seems to consistently
over-predict risk in men by about 5% and shows poor calibration in
women.
Conclusions QRISK2-2011 seems to be a useful model, with good
discriminative and calibration properties when compared with the NICE
version of the Framingham equation. Furthermore, based on current
high risk thresholds, concerns exist on the clinical usefulness of the
NICE version of the Framingham equation for identifying women at high
risk of developing cardiovascular disease. At current thresholds the NICE
version of the Framingham equation has no clinical benefit in either men
or women.
Introduction
Cardiovascular disease is an important health concern,
accounting for nearly one third of deaths worldwide in 2008.
1
In the United Kingdom almost 200 000 deaths annually are
attributed to diseases of the heart and circulatory system, with
more than one in three deaths associated with cardiovascular
disease(www.heartstats.org).Targetinginterventionstoreduce
the risk of cardiovascular disease in high risk patients are now
key components in national policies.
2 3 Risk prediction models,
includingtheFraminghamriskscore,
4theReynoldsriskscore,
5 6
and QRISK
7 8 9 10 11 are tools used to identify people who are at
highrisk(≥20%)
3ofdeveloping(10year)cardiovasculardisease
and could benefit from intervention.
In February 2010 the National Institute for Health and Clinical
Excellence withdrew its recommendation that the Framingham
risk equation be used to predict the risk of someone developing
cardiovascular disease over the next 10 years.
12 This was made
inlightoftheemergenceofanewcardiovascularriskprediction
toolcalledQRISK,
11whichwasshowntohavegreaterpredictive
ability than the Framingham risk equation.
7 8 9 10 11 Despite
increasing evidence to suggest that the Framingham equation
is not well suited to the United Kingdom and that QRISK may
be more suitably tailored, no firm recommendation exists on
what model to use. Instead, NICE no longer recommends any
singleriskscore,leavinghealthcareprofessionalsfreetochoose
the model they consider the most appropriate.
Work has continued on QRISK since its introduction in 2007.
In 2008, QRISK2 (QRISK2-2008) was developed, which was
subsequently updated in 2010 (QRISK2-2010)
13 and again in
2011(QRISK2-2011)(www.qrisk.org)tocaptureimprovements
indataquality.QRISK2(currentlyQRISK2-2011)nowextends
the age range to 30 and 84 years (from 35 to 74 years in
QRISK2-2008). However, the most noticeable modification in
QRISK2-2011 is the change in how smoking status is captured
andincludedinthemodel.EarlierversionsofQRISK2included
smoking status as a binary variable (current smoker versus not
acurrentsmoker),whereasQRISK2-2011nowdefinessmoking
status as a five level category variable: non-smoker, former
smoker, light smoker (<10 cigarettes/day), moderate smoker
(10-19 cigarettes/day), and heavy smoker (≥20 cigarettes/day).
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Research
RESEARCHFinally,theregressioncoefficientsusedtocalculatethe10year
risk of developing cardiovascular disease using QRISK2 have
been recalculated using more up to date and complete data in
the QRESEARCH database (see www.qrisk.org for more
details). QRISK2-2011 includes the risk factors of age (years),
smoking status (non smoker, former smoker, light smoker,
moderate smoker, and heavy smoker), self assigned ethnicity
(white or not recorded, Indian, Pakistani, Bangladeshi, other
Asian,blackAfrican,blackCaribbean,Chinese,otherincluding
mixed race), systolic blood pressure (mm Hg), ratio of total
serum cholesterol to high density lipoprotein, body mass index
(kg/m
2), family history of coronary heart disease in first degree
relative,Townsenddeprivationscore,treatedhypertension,and
diagnosis of rheumatoid arthritis, atrial fibrillation, type 2
diabetes, and chronic renal disease. Table 1⇓ provides a
description of the predictors in the QRISK and Framingham
risk scores. A major feature of QRISK2-2011 is the ability,
using the web calculator (www.qrisk.org) and the recently
developediPhoneapp,tocalculateanindividual’sriskwithone
or more missing risk factors. QRISK2-2011 includes a
mechanism that replaces missing data, with values from
predefined reference values and predictor algorithms.
CalculatingtheriskusingtheNICEversionoftheFramingham
equation requires all information on all risk factors.
Any revisions and updates to a risk prediction model should be
subject to continual evaluation (validation) to show that its
usefulness for routine clinical practice has not deteriorated, or
indeed to show that its performance has improved owing to
refinements to the model.
14 15 We describe the results from an
independent evaluation assessing the performance of
QRISK2-2011 on a large dataset of general practice records in
the United Kingdom, comparing its performance with earlier
versions of QRISK2
7 8 9 10 13 and the NICE adjusted version of
the Framingham risk prediction model.
3 4
Methods
Participants were patients registered between 27 June 1994 and
30June2008andrecordedonTheHealthImprovementNetwork
(THIN) database (www.thin-uk.com). We excluded patients if
they had a previous diagnosis of cardiovascular disease, were
registeredforlessthan12monthswiththegeneralpractice,had
invalid dates, were aged under 30 years, were aged 85 years or
over,hadmissingTownsendscores(socialdeprivation),orwere
prescribed statins at baseline.
Outcome measures
The primary outcome measure was the first diagnosis of
cardiovasculardisease(myocardialinfarction,angina,coronary
heart disease, stroke, and transient ischaemic stroke) recorded
on the general practice’s clinical computer system.
Statistical analysis
Toderivesmokingstatuswecombinedtworiskfactors:whether
thepatientwasanon-smoker,formersmoker,orcurrentsmoker,
and number of cigarettes smoked a day, defined as light (<10),
moderate (10-19), or heavy (≥20).
We calculated the 10 year estimated risk of cardiovascular for
every patient in the THIN cohort using the QRISK2-2011 risk
score. Observed 10 year cardiovascular risks were obtained
usingthemethodofKaplan-Meierby10thofpredictedriskand
age group. To replace missing values for smoking status and
body mass index we carried out multiple imputation using all
predictors plus the outcome variable. This involves creating
multiple copies of the data and imputing the missing values for
each dataset with sensible values randomly selected from their
predicteddistribution.Tenimputeddatasetsweregeneratedand
we combined the results from analyses on each of the imputed
valuesusingRubin’srulestoproduceestimatesandconfidence
intervals that incorporate the uncertainty of imputed values.
16
We assessed the predictive performance of the QRISK2-2011
risk score on the THIN cohort by examining measures of
calibrationanddiscrimination.Calibrationreferstohowclosely
the predicted 10 year cardiovascular risk agrees with the
observed 10 year cardiovascular risk. This was assessed for
each 10th of predicted risk, ensuring 10 equally sized groups
andeachfiveyearageband,bycalculatingtheratioofpredicted
to observed cardiovascular risk separately for men and for
women. Calibration of the risk score predictions was assessed
by plotting observed proportions versus predicted probabilities
and by calculating the calibration slope.
Discrimination is the ability of the risk score to differentiate
between patients who do and do not experience an event during
the study period. This measure is quantified by calculating the
area under the receiver operating characteristic curve statistic;
a value of 0.5 represents chance and 1 represents perfect
discrimination.
17 We also calculated the D statistic and R
2
statistic, which are measures of discrimination and explained
variation, respectively, and are tailored towards censored
survivaldata.
18 19HighervaluesfortheDstatisticindicategreater
discrimination, where an increase of 0.1 over other risk scores
is a good indicator of improved prognostic separation.
19
We used decision curve analysis (accounting for censored
observations) to describe and compare the clinical effects of
QRISK2-2011 and the NICE Framingham equation.
20 21 22 A
model is considered to have clinical value if it has the highest
netbenefitacrosstherangeofthresholdsforwhichanindividual
would be designated at high risk. Briefly, the net benefit of a
modelisthedifferencebetweentheproportionoftruepositives
and the proportion of false positives weighted by the odds of
the selected threshold for high risk designation. At any given
threshold, the model with the higher net benefit is the preferred
model.
All statistical analyses were carried out in R (version 2.13.2)
23
and the ICE (multiple imputation) procedure in Stata (version
11.2).
24
Results
Between 27 June 1994 and 30 June 2008, 2 084 445 eligible
patients, aged between 30 and 84 years, from 364 general
practices in the United Kingdom were registered in the THIN
database. These patients contributed 11 862 381 person years
of observation, during which 93 564 incident cases of
cardiovascular disease occurred. The median follow-up was
5.75 years (interquartile range 2.48-8.49) and 292 928 patients
(14.1%)werefollowedupfor10yearsormore.Table2⇓details
the characteristics of the eligible patients.
In patients aged between 30 and 85 years the 10 year observed
risk of cardiovascular in women (42 224 incident cases of
cardiovascular disease) was 6.57% (95% confidence interval
6.50% to 6.64%) and in men (51 340 incident cases of
cardiovascular disease) was 8.66% (8.58% to 8.75%).
Completedataonsmokingstatus,numberofcigarettessmoked
daily, systolic blood pressure, total serum cholesterol to high
density lipoprotein ratio, and body mass index were available
for 19.6% of women (n=208 570) and 19.0% of men (n=193
825). Most patients (n=1 221 873; 58.6%) had no or only one
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RESEARCHmissing risk factor (table 3⇓). Considerably more data were
missing for total serum cholesterol to high density lipoprotein
ratio(77.9%forwomenand77.7%formen)thanforremaining
risk factors. For other risk factors, 20.6% of women and 29.5%
of men had missing data on body mass index, 8.0% and 18.1%
on systolic blood pressure, 7.3% and 14.3% on smoking status,
and 6.2% and 11.5% on number of cigarettes smoked daily.
The mean absolute difference between QRISK2-2011 and
QRISK2-2010 was −0.16% for women and −0.38% for men.
About 95.6% of women and 98.3% of men had QRISK2-2011
scores within 2% and 3% of the QRISK2-2010, respectively.
The mean absolute difference between QRISK2-2011 and the
originalQRISK2-2008predictedriskswas−0.40%and−0.73%
for women and men, respectively, and about 93% and 97% of
all women and men will have QRISK2-2011 scores within 2%
and 3% of the QRISK2-2008 scores, respectively.
Discrimination and calibration
Figure 1⇓ shows the calibration plots for the three versions of
QRISK2 and the NICE version of the Framingham equation.
ThecurrentversionofQRISK2anditspredecessorsshowmuch
better agreement between the observed risk and the predicted
risk grouped by 10th of risk than does the NICE Framingham
equation. All three versions of the QRISK2 prediction models
show good calibration in all 10ths of risk, with the exception
of the final 10th in both men and women (calibration slope,
range 0.92-0.95). Similarly, Figure 2⇓ shows the agreement
between observed risk and predicted risk by age group for each
of the QRISK2 prediction models and the NICE Framingham
equation. All the QRISK2 prediction models show good
agreement across the age groups, with a small divergence
observed towards the latter age ranges (75 to 85 years). The
NICEFraminghamequationis,however,clearlymiscalibrated,
most noticeably for men, with a near constant over-prediction
of about 5% across all age ranges (35-74 years). The observed
risk across age groups in women shows a non-linear trend
increasing with age, while the corresponding predicted risks
exhibitalineartrendsuggestingthatageisnotbeingadequately
captured in this cohort of UK women.
Table 4⇓ presents performance data for the QRISK prediction
models and the NICE Framingham equation. The R
2 statistic
(percentageofexplainedvariation)issimilarforQRISK2-2011
and QRISK2-2010 in men and women aged 30 to 84 years,
indicating no change in performance of the newer QRISK2
model. Values for R
2, restricted to those aged 35 to 74 years to
enable comparison with the NICE Framingham equation, are
about 4% to 5% higher for the QRISK2 models. The D
discrimination statistic, where a higher score denotes better
discrimination is higher (between 0.14 and 0.19 higher) for the
QRISK2 models compared with the NICE Framingham
equation, indicating improved prognostic separation. Finally,
the area under the receiver operating characteristic curve is
about 0.02 higher for QRISK2 in both men and women
(restrictedtothoseaged35to74years),whereaslittledifference
isobservedbetweenQRISK2-2011andQRISK2-2010inthose
aged 30 to 84 years.
Decision curve analysis
Table 5⇓ shows how many of 1000 people would be identified
as being at high risk (based on thresholds of 10%, 15%, and
20%) using either QRISK2-2011 or the NICE Framingham
equation, and how many of these go on to experience a
cardiovascular event compared with a strategy where all
individuals are deemed at high risk. For women aged between
35 and 74 years there seems to be little difference between the
two models, with both identifying similar numbers of women
who experience a cardiovascular event. However, many more
women would be incorrectly flagged as being at increased risk
usingtheNICEFraminghamequation.Table5alsosubstantiates
our earlier findings that in men aged between 35 and 74 years
the NICE Framingham equation is currently over-predicting
their risk of developing cardiovascular disease by about 5%.
This table shows the similarity in the numbers of men who are
identified at high risk and those who go on to experience a
cardiovascular event if the NICE Framingham at 20% is
comparedwithQRISK2-2011at15%ortheNICEFramingham
equation at 15% is compared with QRISK2-2011 at 10%.
Figure 3⇓ displays the net benefit curves for QRISK2-2011,
QRISK2-2008, and the NICE Framingham equation for people
aged between 35 and 74 years. At the traditional threshold of
20% used to designate an individual at high risk of developing
cardiovasculardisease,thenetbenefitofQRISK2-2011formen
is that the model identified five more cases per 1000 without
increasing the number treated unnecessarily when compared
withtheNICEFraminghamequation.Forwomenthenetbenefit
of using QRISK2-2011 at a 20% threshold identified two more
casesper1000comparedwithnotusinganymodel(ortheNICE
Framingham equation). There seems to be no net benefit in
using the 20% threshold for the NICE Framingham equation
foridentifyingwomenwhoareatanincreasedriskofdeveloping
cardiovascular disease over the next 10 years. Both QRISK2
models perform similarly and clearly show greater net benefit
across a range of thresholds compared with the NICE
Framingham equation.
Discussion
We carried out an independent evaluation of the performance
of QRISK2-2011 on a large cohort of general practice patients
using The Health Improvement Network (THIN) database,
comprisingtwomillionpatientscontributing11862252person
years of observation. The performance data presented in this
article provide strong evidence for use of the updated
QRISK2-2011 over the NICE Framingham equation. The
performance of QRISK2-2011 is noticeably more impressive
than the NICE version of the Framingham equation in
discrimination,calibration,andclinicalutility.Theperformance
of QRISK2-2011 and its predecessor QRISK2-2010 are
comparable,withnosuggestionofdeteriorationinperformance.
TheNICEFraminghammodelformenisclearlymiscalibrated,
over-predicting the 10 year risk of developing cardiovascular
disease by about 5%. For women, the equation seems to be
performing poorly, with evidence to suggest that the model is
inadequately capturing age. Furthermore, we have shown that
the NICE Framingham equation has no clinical utility at the
current threshold to identify those who are at an increased risk
of developing cardiovascular disease. If the Framingham
equation is to continue to be used and doctors advised to treat
patients if their predicted risk is 20% or higher, then it is
necessary for it to be recalibrated and updated to reflect current
characteristics of the UK population. Without recalibration we
urge caution in using the Framingham equation to identify high
risk patients in the United Kingdom.
Strengths and limitations of the study
A major strength of this study is the size and the
representativeness of the cohort, by including a large number
of general practices using the EMIS computer system. A
limitation of this study is the considerable amounts of missing
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RESEARCHdata for total serum cholesterol to high density lipoprotein ratio
both in the derivation and the external validation of
QRISK2-2011. Despite the large amounts of missing data,
informationonallriskfactorswereavailablefor400000people,
and 800 000 people had none or only one missing risk factor.
However, we used current recommended approaches with
multiple imputation to overcome the biases that occur when
omitting people with incomplete data.
25 26
Conclusions
We have provided an independent and external validation of
QRISK2-2011 on a large cohort of general practice patients in
the United Kingdom to predict the 10 year risk of developing
cardiovascular disease. We have shown that the updated
QRISK2-2011 model has not incurred any deterioration in
performance and shows good potential clinical utility in
predicting the risk of cardiovascular disease in those aged
between 30 and 85 years. Furthermore, we have shown that
QRISK2-2011continuestobeaconsiderableimprovementover
the NICE modification of the Framingham equation. For the
Framingham equation to be even considered along side
QRISK2-2011 for predicting the 10 year risk of developing
cardiovascular disease, at a minimum we recommend that it
shouldbeupdatedandcalibratedtotheUKpopulation.Finally,
the current high risk threshold of 20% adopted by NICE to
designate those at high risk of cardiovascular disease may need
to be revisited, and there are likely to be different thresholds
for women and men.
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RESEARCHWhat is already known on this topic
Until recently cardiovascular risk prediction in the United Kingdom has been based on a NICE adjusted version of the US Framingham
model, which has been shown to over-predict risk
QRISK2 was developed using a large cohort of UK patients and published in 2008 and updated in 2010 and 2011
Updated risk prediction models need to be independently and externally validated to objectively evaluate performance
What this study adds
Independent evaluation of QRISK2-2011 showed an improvement in performance over the NICE Framingham equation in a large
external cohort of UK patients
Using current thresholds (20%) to designate those at high risk, the NICE Framingham equation has been shown to have no clinical
usefulness in men or women
The NICE Framingham equation has been shown to consistently over-predict the 10 year risk of cardiovascular disease in men by about
5%
Tables
Table 1| Summary of risk factors in QRISK2-2008, QRISK2-2011, and National Institute for Health and Clinical Excellence version of
Framingham equation
NICE Framingham equation QRISK2-2011 QRISK2-2008
Age (continuous) (35-74 years) Age (continuous) (30-84 years) Age (continuous) (35-74 years)
Ratio of total serum cholesterol to high
density lipoprotein (continuous)
Ratio of total serum cholesterol to high density lipoprotein
(continuous)
Ratio of total serum cholesterol to high density lipoprotein
(continuous)
Systolic blood pressure (continuous) Systolic blood pressure (continuous) Systolic blood pressure (continuous)
Smoking status (current smoker (or quit
within past year), non-smoker)
Smoking status (non-smoker, former smoker, light smoker,
moderate smoker, heavy smoker)
Smoking status (current smoker, non-smoker (including
former smoker))
Sex (male, female) Body mass index (continuous) Body mass index (continuous)
Left ventricular hypertrophy (yes/no) Family history of coronary heart disease in first degree relative
<60 years (yes/no)
Family history of coronary heart disease in first degree
relative <60 years (yes/no)
Type 2 diabetes (yes/no) Townsend deprivation score (output area level 2001 census
data evaluated as continuous variable)
Townsend deprivation score (output area level 2001 census
data evaluated as continuous variable)
Age×type 2 diabetes Treated hypertension (diagnosis of hypertension and at least
one current prescription of at least one antihypertensive agent)
(yes/no)
Treated hypertension (diagnosis of hypertension and at least
one current prescription of at least one antihypertensive
agent) (yes/no)
Left ventricular hypertrophy×age Self assigned ethnicity (white/not recorded, Indian, Pakistani,
Bangladeshi, other Asian, black African, black Caribbean,
other included mixed)
Self assigned ethnicity (white/not recorded, Indian, Pakistani,
Bangladeshi, other Asian, black African, black Caribbean,
other included mixed)
Age×sex Type 2 diabetes (yes/no) Type 2 diabetes (yes/no)
Rheumatoid arthritis (yes/no) Rheumatoid arthritis (yes/no)
— Atrial fibrillation (yes/no) Atrial fibrillation (yes/no)
— Renal disease (yes/no) Renal disease (yes/no)
— Age×body mass index Age×body mass index
— Age×Townsend score Age×Townsend score
— Age×systolic blood pressure Age×systolic blood pressure
— Age×family history of cardiovascular disease Age×family history of cardiovascular disease
— Age×smoking current Age×smoking current
— Age×treated hypertension Age×treated hypertension
— Age×type 2 diabetes Age×type 2 diabetes
— Age×atrial fibrillation Age×atrial fibrillation
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RESEARCHTable 2| Characteristics of patients aged 30 to 84 years in The Health Improvement Network database. Values are numbers (percentages)
of patients unless stated otherwise
Men (n=1 018 318) Women (n=1 066 127) Characteristics
47.7 (13.4) 49.6 (14.7) Mean (SD) age (years)
26.5 (4.1) 26.0 (5) Mean (SD) body mass index (mg/kg
2)
300 787 (29.5) 220 012 (20.6) Body mass index not recorded
134.3 (19.0) 130.5 (21.3) Mean (SD) systolic blood pressure (mm Hg)
183 852 (18.1) 84 802 (8.0) Systolic blood pressure not recorded
4.5 (1.4) 3.9 (1.2) Mean (SD) total cholesterol: HDL cholesterol ratio
791 281 (77.7) 830 407 (77.9) Total cholesterol: HDL cholesterol ratio not recorded
Smoking status:
440 245 (43.2) 608 942 (57.1) Non-smoker
180 952 (17.8) 154 544 (14.5) Former smoker
Current smoker (cigarettes/day):
56 176 (5.5) 58 254 (5.5) Light (<10)
92 200 (9.1) 96 970 (9.1) Moderate (10-19)
102 955 (10.1) 69 517 (6.5) Heavy (≥20)
29 072 (2.9) 11 760 (1.1) Amount not recorded
116 718 (11.5) 66 140 (6.2) Smoking status not recorded
Ethnic group:
994 798 (97.7) 1 041 209 (97.7) White/not recorded
5907 (0.6) 5793 (0.5) Indian
1786 (0.2) 1648 (0.2) Pakistani
708 (0.1) 520 (0.1) Bangladeshi
2774 (0.3) 2887 (0.3) Other Asian
2238 (0.2) 2893 (0.3) Black Caribbean
3900 (0.4) 4422 (0.4) Black African
848 (0.1) 1142 (0.1) Chinese
5359 (0.5) 5613 (0.5) Other, including mixed race
Clinical condition:
45 079 (4.4) 68 061 (6.4) Treated hypertension
22 056 (2.2) 18 295 (1.7) Type 2 diabetes
38 491 (3.8) 46 974 (4.4) Family history of early coronary heart disease
7474 (0.7) 6276 (0.6) Atrial fibrillation
1467 (0.1) 1579 (0.15) Chronic renal disease
51 340 42 224 Cardiovascular disease*
5 702 452 6 159 929 Person years of observation
HDL=high density lipoprotein.
*Cardiovascular disease events before death and deaths due to cardiovascular disease.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e4181 doi: 10.1136/bmj.e4181 (Published 21 June 2012) Page 6 of 12
RESEARCHTable 3| Completeness of data
No (%) of men (n=1 018 318) No (%) of women (n=1 066 127) No of risk factors not recorded (per patient)
193 825 (19.0) 208 570 (19.6) 0 (complete data)
183 852 (49.2) 635 626 (59.6) 1
140 028 (13.8) 127 290 (11.9) 2
70 692 (6.9) 33 791 (3.2) 3
19 337 (1.9) 16 568 (1.6) 4
93 628 (9.2) 44 282 (4.2) 5
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RESEARCHTable 4| Performance data on QRISK2 and NICE Framingham equation on The Health Improvement Network
AUROC (95% CI) D statistic (95% CI) R
2 (95% CI) Model
Women aged 30-84:
0.835 (0.834 to 0.837) 1.98 (1.96 to 1.99) 48.3 (47.9 to 48.7) QRISK2-2011
0.835 (0.833 to 0.837) 1.97 (1.95 to 1.99) 48.1 (47.7 to 48.6) QRISK2-2010
Men aged 30-84:
0.809 (0.807 to 0.811) 1.73 (1.71 to 1.75) 41.6 (41.2 to 42.0) QRISK2-2011
0.811 (0.809 to 0.812) 1.76 (1.74 to 1.77) 42.5 (42.0 to 42.8) QRISK2-2010
Women aged 35-74:
0.802 (0.800 to 0.804) 1.67 (1.65 to 1.69) 40.1 (39.5 to 40.6) QRISK2-2011
0.800 (0.798 to 0.803) 1.66 (1.56 to 1.76) 39.5 (36.6 to 42.4) QRISK2-2008
Men aged 35-74:
0.771 (0.769 to 0.773) 1.44 (1.42 to 1.46) 33.1 (32.6 to 33.6) QRISK2-2011
0.772 (0.769 to 0.774) 1.45 (1.31 to 1.59) 33.3 (28.9 to 37.8) QRISK2-2008
Women aged 35-74:
0.776 (0.773 to 0.779) 1.48 (1.46 to 1.50) 34.2 (33.6 to 34.9) NICE Framingham equation
Men aged 35-74:
0.750 (0.747 to 0.752) 1.31 (1.30 to 1.33) 29.2 (28.7 to 29.7) NICE Framingham equation
AUROC=area under receiver operating characteristic curve.
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RESEARCHTable 5| Clinical outcomes basing treatment on varying high risk thresholds (5%, 10%, 15%, and 20%)
No of high risk cardiovascular events No of people at risk
Sexes per 1000 Not identified Identified Low risk High risk
Women aged 35 to 74
0 37 0 1000 Treat all*
QRISK2-2011:
7 29 644 356 ≥5%
15 22 806 194 ≥10%
23 14 896 104 ≥15%
29 8 952 48 ≥20%
NICE Framingham:
14 23 745 255 ≥10%
22 14 872 128 ≥15%
28 9 937 63 ≥20%
Women aged 30 to 85
0 40 0 1000 Treat all*
QRISK2-2011:
6 34 656 344 ≥5%
12 28 778 222 ≥10%
17 23 844 156 ≥15%
23 17 891 109 ≥20%
Men aged 35 to 74
0 54 0 1000 Treat all*
QRISK2-2011:
7 47 496 504 ≥5%
17 38 691 309 ≥10%
27 27 809 191 ≥15%
36 18 890 110 ≥20%
NICE Framingham:
9 45 506 494 ≥10%
18 36 678 322 ≥15%
27 27 794 206 ≥20%
Men aged 30 to 85
0 50 0 1000 Treat all*
QRISK2-2011:
6 45 565 435 ≥5%
13 37 716 284 ≥10%
21 29 807 193 ≥15%
28 22 871 129 ≥20%
*All high risk people.
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RESEARCHFigures
Fig 1 Observed versus predicted 10 year risk of cardiovascular disease (CVD)
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RESEARCHFig 2 Observed and predicted 10 year risk of cardiovascular disease (CVD) by age group and sex
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RESEARCHFig 3 Decision curves for participants aged 34 to 75 years in The Health Improvement Network
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RESEARCH